Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
Xeris Biopharma Holdings (Nasdaq: XERS) has scheduled the release of its third quarter 2024 financial results before U.S. market opening on November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. ET. The company, focused on developing innovative therapies, currently markets three products: Gvoke® for severe hypoglycemia, Keveyis® for primary periodic paralysis, and Recorlev® for endogenous Cushing's syndrome.
Xeris Biopharma Holdings (Nasdaq: XERS) ha programmato il rilascio dei suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura del mercato negli Stati Uniti l'8 novembre 2024. La direzione terrà una chiamata in conferenza e un webcast alle 8:30 a.m. ET. L'azienda, focalizzata sullo sviluppo di terapie innovative, attualmente commercializza tre prodotti: Gvoke® per l'ipoglicemia severa, Keveyis® per la paralisi periodica primaria, e Recorlev® per la sindrome di Cushing endogena.
Xeris Biopharma Holdings (Nasdaq: XERS) ha programado la publicación de sus resultados financieros del tercer trimestre 2024 antes de la apertura del mercado en EE. UU. el 8 de noviembre de 2024. La dirección realizará una llamada de conferencia y una transmisión web a las 8:30 a.m. ET. La compañía, centrada en el desarrollo de terapias innovadoras, actualmente comercializa tres productos: Gvoke® para la hipoglucemia severa, Keveyis® para la parálisis periódica primaria y Recorlev® para el síndrome de Cushing endógeno.
Xeris Biopharma Holdings (Nasdaq: XERS)는 2024년 11월 8일 미국 시장 개장 전에 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 경영진은 동부 표준시 기준 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 개최합니다. 혁신적인 치료법 개발에 집중하는 이 회사는 현재 Gvoke® (심각한 저혈당), Keveyis® (원발성 주기성 마비), 그리고 Recorlev® (내인성 쿠싱 증후군) 등 세 가지 제품을 판매하고 있습니다.
Xeris Biopharma Holdings (Nasdaq: XERS) a prévu de publier ses résultats financiers du troisième trimestre 2024 avant l'ouverture du marché aux États-Unis le 8 novembre 2024. La direction animera une conférence téléphonique et un webinaire à 8h30 ET. L'entreprise, axée sur le développement de thérapies innovantes, commercialise actuellement trois produits : Gvoke® pour l'hypoglycémie sévère, Keveyis® pour la paralysie périodique primaire, et Recorlev® pour le syndrome de Cushing endogène.
Xeris Biopharma Holdings (Nasdaq: XERS) hat die Veröffentlichung seiner finanziellen Ergebnisse für das dritte Quartal 2024 vor der Eröffnung des US-Marktes für den 8. November 2024 geplant. Das Management wird um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten. Das Unternehmen, das sich auf die Entwicklung innovativer Therapien konzentriert, vermarktet derzeit drei Produkte: Gvoke® bei schwerer Hypoglykämie, Keveyis® bei primärer periodischer Lähmung und Recorlev® bei endogenem Cushing-Syndrom.
- None.
- None.
Conference call and webcast at 8:30am ET
To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=6c5018a9&confId=72180. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Friday, November 22, 2024 at US:1 929 458 6194, US Toll Free: 1 866 813 9403,
To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/232807470
Xeris Biopharma Holdings, Inc.
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect®, to support long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031125180/en/
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
When will Xeris Biopharma (XERS) release Q3 2024 earnings?
What time is Xeris Biopharma's (XERS) Q3 2024 earnings call?
What products does Xeris Biopharma (XERS) currently market?
